M&A / Deals Zydus to acquire Assertio in $166m deal Pharmaceutical TechnologyZydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.Read full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaceutical Technology Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer receives EC approval for Hympavzi to treat haemophiliaNext: ECO 2026: gut hormone signals differ in T1D with obesity Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
